Introduction to the Genomics special edition on clinical and translational genomics
This journal was conceived and created when genomics was a young science, described in Volume 1, issue 1 as, "a new discipline [with] a new name." For more than 25 years Genomics has reported on the development and application of cutting-edge methods in genomic technology and has published manuscripts addressing fundamental questions in genome biology. The goal has been to present high-quality work to a broad audience that is eager to consume the dynamically-evolving knowledge base characteristic of this field. This mission has mandated that we present content not only limited to fundamental genomics, but also spanning a variety of genomic subspecialties, including epigenomics, evolutionary and comparative genomics, genomic technology, computational biology, genomic-scale genetics, genomics regulatory analysis, and disease-related genomics. The result has been a track record for publishing valuable additions to the genomic literature and the development of a loyal readership base that values this content.
As genomics continues to mature, we are now entering a period where novel developments continue but, in addition, validated methods are being used in both preclinical and clinical settings to investigate, diagnose, and treat human disease. These are the early days of the era that we envisioned some 25 years ago: the fruition of the latter half of the often-cited "bench to bedside" model for translational genomics research. As part of the journal's ongoing effort to remain on the cutting edge of genomics, the time seemed appropriate to reiterate and emphasize our commitment to publishing reports of high-quality preclinical and clinical translational genomics investigations. For this reason we have designated this issue as a "special edition on clinical and translational genomics" and have taken the opportunity to showcase some of the types of applied genomics investigations that we believe represent a critical part of the future scope of Genomics.
As this edition's selection of articles illustrates, the topic of "clinical and translational genomics" encompasses a broad spectrum of subjects. Specific topics of interest to Genomics include such diverse issues as associations between genomic signatures and therapeutic response, genomic markers of clinical risk and prognosis, molecular subgroups of diseases that have clinically-relevant phenotypic differences, mathematical and computational models for analyzing genomic data in a clinical context, or any of a number of others. While they may appear superficially dissimilar, these topics are all fundamentally unified in their focus on using novel genomic innovations and technologies to address practical challenges in clinical patient management. We believe that this category of research represents an important part of the future of genomics-both the journal and the discipline on which it reports.
While we continue to welcome basic science investigations related to any and all constituents of the broad discipline of genomics, we also invite applied researchers, translational investigators, and clinicians with expertise in genomics to submit manuscripts detailing current and future applications of genome technologies to clinical decision-making and to patient care. We look forward to incorporating such reports into the comprehensive repertoire of research on which Genomics reports, and we believe that the efforts to these ends will help keep this journal focused on the leading edge of modern genomics.
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